Publication date: Sep 25, 2025
Risk of Post-COVID Conditions among adolescents and adults who received nirmatrelvir-ritonavir for acute COVID-19: a retrospective cohort study. Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia. Pharmacists should counsel patients that the best way to prevent the development of PCC is to protect themselves from being infected with COVID-19 and experiencing severe symptoms through vaccination. REFERENCES1. Patients eligible for inclusion had a COVID-19 index date from April 1 through August 31, 2022, in the outpatient, telehealth, or emergency department setting. [Nirmatrelvir-ritonavir] remains an important tool to reduce the pandemics public health burden by preventing hospitalization and death due to acute COVID-19. Halpern L. Nirmatrelvir-Ritonavir Has Little Impact on COVID-19 Hospitalization, Mortality in Vaccinated Older Adults. Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status.
| Concepts | Keywords |
|---|---|
| Month | Acute |
| Outpatient | Adults |
| Ucla | Ci |
| Covid | |
| Incidence | |
| Long | |
| Nirmatrelvir | |
| Older | |
| Pcc | |
| Protective | |
| Risk | |
| Ritonavir | |
| Symptoms | |
| Treatment | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Ritonavir |
| disease | MESH | long COVID |
| disease | IDO | acute infection |
| disease | MESH | death |
| disease | MESH | emergency |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | health status |
| drug | DRUGBANK | Factor IX Complex (Human) |
| disease | MESH | Infectious Diseases |
| disease | MESH | COVID-19 |